Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ragweed Allergy - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Ragweed Allergy - Pipeline Review, H1 2016', provides an overview of the Ragweed Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy - The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects - The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ragweed Allergy Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ragweed Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Ragweed Allergy - Overview 7 Ragweed Allergy - Therapeutics under Development by Companies 8 Ragweed Allergy - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Unknown Stage Products 11 Ragweed Allergy - Products under Development by Companies 12 Ragweed Allergy - Companies Involved in Therapeutics Development 13 Anergis SA 13 Biomay AG 14 Circassia Pharmaceuticals Plc 15 Immunomic Therapeutics, Inc. 16 Stallergenes S.A. 17 Ragweed Allergy - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 Allergen for Ragweed Allergy - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Allergen for Ragweed Pollen Allergy - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AllerR - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BM-34 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Multi-LAMP-Vax - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PL-101 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Ragweed Allergy - Recent Pipeline Updates 32 Ragweed Allergy - Dormant Projects 34 Ragweed Allergy - Discontinued Products 35 Ragweed Allergy - Product Development Milestones 36 Featured News & Press Releases 36 Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR 36 Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study 36 Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting 37 Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones with Ragweed Pollen Vaccine 38 Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 39 Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
Number of Products under Development for Ragweed Allergy, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Comparative Analysis by Unknown Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Ragweed Allergy - Pipeline by Anergis SA, H1 2016 13 Ragweed Allergy - Pipeline by Biomay AG, H1 2016 14 Ragweed Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 15 Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2016 16 Ragweed Allergy - Pipeline by Stallergenes S.A., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Ragweed Allergy Therapeutics - Recent Pipeline Updates, H1 2016 32 Ragweed Allergy - Dormant Projects, H1 2016 34 Ragweed Allergy - Discontinued Products, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.